药品注册申请号:205941
申请类型:ANDA (仿制药申请)
申请人:AMNEAL
申请人全名:AMNEAL PHARMACEUTICALS LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE No No AB 2023/07/31 2023/07/31 Discontinued
002 SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE No No AB 2023/07/31 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/07/31 ORIG-1(原始申请) Approval STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 PC 2024/01/27
002 PC 2024/01/27
与本品治疗等效的药品
活性成分:SAXAGLIPTIN HYDROCHLORIDE 剂型/给药途径:TABLET;ORAL 规格:EQ 2.5MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022350 001 NDA ONGLYZA SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE Discontinued Yes No AB 2009/07/31 ASTRAZENECA AB
205941 001 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE Discontinued No No AB 2023/07/31 AMNEAL
205972 001 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE Prescription No No AB 2023/07/31 AUROBINDO PHARMA
205980 001 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE Prescription No No AB 2023/07/31 MYLAN
205994 001 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE Prescription No No AB 2023/07/31 GLENMARK PHARMS LTD
206078 001 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 2.5MG BASE Prescription No No AB 2023/07/31 SUN PHARM
活性成分:SAXAGLIPTIN HYDROCHLORIDE 剂型/给药途径:TABLET;ORAL 规格:EQ 5MG BASE 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
022350 002 NDA ONGLYZA SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE Discontinued Yes No AB 2009/07/31 ASTRAZENECA AB
205941 002 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE Discontinued No No AB 2023/07/31 AMNEAL
205972 002 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE Prescription No No AB 2023/07/31 AUROBINDO PHARMA
205980 002 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE Prescription No Yes AB 2023/07/31 MYLAN
205994 002 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE Prescription No No AB 2023/07/31 GLENMARK PHARMS LTD
206078 002 ANDA SAXAGLIPTIN SAXAGLIPTIN HYDROCHLORIDE TABLET;ORAL EQ 5MG BASE Prescription No No AB 2023/07/31 SUN PHARM
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database